Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell TransplantationAlan P Skarbnik, Andrew L. Pecora, Lori A. Leslie et al.|Transplantation and Cellular Therapy|2020Cited by 16
Day 90 Post-Allogeneic Hematopoietic Cell Transplantation T Cell Receptor Diversity Level Correlates with Risk of Relapse in Patients with Multiple MyelomaRobert Korngold, Michèle L. Donato, Kira Goldgirsh et al.|Blood|2017Cited by 2
Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant RecurrenceRena Feinman, Andrew L. Pecora, Tracy Andrews et al.|Blood|2018Cited by 0
Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant RecurrenceJamie Koprivnikar, Andrew L. Pecora, Rena Feinman et al.|Blood|2019Cited by 0